Kornimate/medical-research-clean huggingface dataset:
cross-sectional study of chinese liver cancer patients

Conditions: Liver Cancer

Summary: the goal of this cross-sectional study is to investigate the prevalence and risk factors of anxiety and depression and their relationships with immune functions and quality of life among liver cancer patients in the covid-19 pandemic era. the objectives of this study are: 1. to examine the prevalence of anxiety and depression among patients with liver cancer during the covid-19 pandemic. 2. to identify risk factors associated with anxiety and depression among these patients. 3. to determine the association between anxiety, depression, immune function, and quality of life among liver cancer patients. participants will be asked to fill a digital questionnaire.


Eligibility criteria:
inclusion criteria participants must meet all the following criteria for study entry: 1. aged 18 or older. 2. participants have a confirmed diagnosis of liver cancer in the medical records. 3. participants are able to communicate with chinese. exclusion criteria participants who meet any of the following criteria will be excluded from study entry: 1. participant has multiple organ failure which makes him/her incapable to comply with the study protocol. 2. participant has hepatic encephalopathy or severe mental disorder which makes him/her incapable of understanding the meanings of the questionnaires.
sensitivity and specificity of the roth test in patients with covid-19 positive

Conditions: Covid19

Summary: the presence of the described silent hypoxia in subjects diagnosed with covid19 highlights the need for valid tools to assess respiratory capacity. the roth test has been associated with acceptable sensitivity and specificity criteria in patients with previous respiratory pathology; however, its validity in this type of patient has not been proven.


Eligibility criteria:
inclusion criteria: 1. having been diagnosed as covid-19 positive and with symptoms compatible with sars-cov-2 infection in the last 7 days prior to assessment, 2. having an understanding of spanish, 3. and having no history of respiratory pathology prior to the current infection.
daily bi-temporal transcranial random noise stimulation in tinnitus

Conditions: Chronic Tinnitus

Summary: stimulation of the left and right auditory cortex with daily transcranial random noise stimulation (trns) is used to modulate the neural pathways involved in chronic tinnitus.

tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. it is a frequent problem which can interfere significantly with the ability to lead a normal life. tinnitus has been shown to be generated in the brain, as a result of functional reorganization of auditory neural pathways and the central auditory system. these changes are represented by hyper-activity and hyper-synchronicity in the auditory pathway. treatment remains difficult. non-invasive brain stimulation methods has shown to be effective in the treatment of chronic tinnitus with moderate effect size. preliminary data presented on international conferences suggest the use of transcranial random noise stimulation (trns) over both auditory cortices as new and highly effective treatment. high-frequency (hf; 100-650hz) trns might be highly effective in tackling hyper-synchronised cell assemblies. daily hf-trns (2 weeks) will be examined with regard to feasibility, safety and clinical efficacy in patients suffering from chronic tinnitus in an one-arm pilot trial.

Eligibility criteria:
inclusion criteria: * diagnosis of bothersome, subjective chronic tinnitus * diagnosis: duration of tinnitus more than 6 months exclusion criteria: * objective tinnitus * irregular head shap below the electrodes * eczema on the head * treatable cause of the tinnitus * involvement in other treatments for tinnitus at the same time * clinically relevant psychiatric comorbidity * clinically relevant unstable internal or neurological comorbidity * history of or evidence of significant brain malformation or neoplasm, head injury * cerebral vascular events * neurodegenerative disorder affecting the brain or prior brain surgery * metal objects in and around body that can not be removed * pregnancy * alcohol or drug abuse

Keywords: tinnitus transcranial random noise stimulation trns auditory cortex non-invasive brain stimulation
tranxemic acid and vitamin k injection to control upper gastrointestinal bleeding in cirrhotic patients

Conditions: Upper Gastrointestinal Bleeding (UGIB); Variceal Bleeding; Cirrhosis

Summary: the goal of this randomized controlled clinical trial is to evaluate the efficacy of tranexamic acid and vitamin k injection versus placebo in control of upper gastrointestinal bleeding (ugib) in egyptian cirrhotic patients. researchers will compare the bleeding and mortality rates (at 5 days and 6 weeks post endoscopic intervention for ugib) between patients receiving tranxemic acid and vitamin k injection and patients receiving placebo. participants presenting with variceal bleeding will be randomly assigned to receive tranexamic acid (1 g loading dose followed by 3 g maintenance dose over 24- 48 hours) and intravenous injection of 10 mg daily of vitamin k for 24-48 h or matching placebo group receiving iv saline. intervention will be carried out besides the recommended initial management of airway management, hemodynamic stabilization, octreotide analogue, ppi, antibiotics, and endoscopy. follow-up all patients will be kept at the hospital for at least 5 days from the index bleed and will be discharged if no other reason was observed to keep them at the hospital. the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate were evaluated and compared across the groups. at discharge, all patients will be started on nonselective beta-blockers if there was no contraindication. they will be given instructions to attend to hospital if they noticed any melena or hematemesis. second follow-up after 6 weeks for the rebleeding rate and mortality related to bleeding rate.


Eligibility criteria:
inclusion criteria: * age ≥18 years * liver cirrhosis * upper gastrointestinal bleeding exclusion criteria: * patients aged \< 18 years * allergy to tranexamic acid * allergy to vitamin k injection * dic. * thromboembolic event. * pregnancy or lactation. * end-stage renal disease. * unwilling to participate in our study.

Keywords: variceal bleeding tranexamic acid and vitamin k liver cirrhosis
comparative single-dose bioavailability clinical study of different coenzyme q10 products

Conditions: Coenzyme Q Deficiency

Summary: the randomized, open-label, three period crossover single-dose bioavailability study with three coenzyme q10 products

the randomized, open-label, three period crossover single-dose bioavailability study with three coenzyme q10 products will include 25 subjects who will test three different coenzyme q10 products. serum concentration of coenzyme q10 will be measured.

Eligibility criteria:
inclusion criteria: * subject informed consent form * aged between 40 and 55 years old * body mass for women 65± 5 kg and for men 85± 5 kg * non-smoking * healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases * absence of any prescribed medication during the study * willing to avoid a consumption of any food supplements at least 2 weeks before and during the study * willing to study all study procedures exclusion criteria: * cardio-vascular diseases, * diabetes, * neurodegenerative diseases, * gastrointestinal disorders * hypotension * pregnancy * breast-feeding * intake of any prescribed medication within two week of the beginning of the study * intake of any food supplements within two week of the beginning of the study * drug or alcohol abuse

Keywords: coenzyme q10 single dose bioavailability
response to influenza vaccination in lymphoma patients treated with rituximab

Conditions: Non-Hodgkin Lymphoma (NHL)

Summary: the purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma. secondly to study the immune-response to vaccination with influenza virus vaccine, after treatment with rituximab in relation to the reconstitution of immune-function.


Eligibility criteria:
inclusion criteria: 1. patients with non-hodgkin's lymphoma, treated with rituximab (with a range of 6-12 cycles) and who are in remission. 2. completion of rituximab therapy in the last twelve months before start of the study. 3. age ≥ 18 years. 4. signing of informed consent. exclusion criteria: 1. completion of rituximab therapy 7-8 months before start of the study. 2. fever at time of vaccination. 3. previous/known allergic reaction to any of the components of the vaccines given.

Keywords: nhl influenza vaccination rituximab
ngs diagnostic in covid-19 hosts - genetic cause relating to the course of disease progression

Conditions: COVID-19

Summary: in this study (i) the host genome to identify susceptibility regions of infection, inflammation, and host defense, (ii) host response to severe acute respiratory syndrome-corona-virus-2 (sars-cov-2) infection, and (iii) viral sequence composition to define viral sequences which may be correlated with disease severity in addition to the metagenome of the throat swab will be analysed .

this study aims to recruit adult persons with diagnostically confirmed corona-virus- disease-19 (covid-19) infection and with different disease manifestation who are included into diagnostic or therapeutic care at the university hospital tübingen (ukt). the covid-19 next-generation-sequencing (ngs) study aims to cover as many patients in germany as possible. it is expected to include in phase 1 (pilot study): 250 patients with different disease manifestation (extreme phenotypes) and individual risk factors by whole genome analysis phase 2 (verification study): 1.000 clinically well-defined patients to ensure a broader range of overlapping phenotypes, to verify data from the pilot study. phase 3 (confirmation study): \> 10.000 patients to increase the power (anticipated).

Eligibility criteria:
inclusion criteria: * covid-19 infection confirmed * covid-19 disease manifestation * age \> 18 years exclusion criteria: * missing informed consent of the patient/ legal guardian/ relatives

Keywords: covid-19 sars-cov-2 next-generation-sequencing whole genome analysis multiomics extreme phenotypes
a comparison of pf708 and forteo in osteoporosis patients

Conditions: Osteoporosis

Summary: the purpose of this study is to compare the effects of two teriparatide products, pf708 and forteo, in patients with osteoporosis.

this is a randomized, multi-center study conducted in the united states. men and women with osteoporosis will be enrolled in a parallel-group, open-label study design to compare the effects of pf708 and forteo after 24 weeks of treatment. half of the subjects will be randomized to receive pf708, and the other half will be randomized to receive forteo.

Eligibility criteria:
inclusion criteria: * if female, ≥5 years postmenopausal at the time of screening, with a dxa-derived bmd value at least 1 standard deviation (sd) below the average of young, healthy women * if male, has a dxa-derived bmd value at least 2 sd below the average of young, healthy men * able to use the pen injection device correctly * able to understand and sign the written informed consent form (icf) exclusion criteria: * treatment with oral bisphosphonates (once daily or once weekly) within 6 months of screening * any current or prior human pth-derived products (e.g., forteo, teribone, natpara), including for investigational purposes * immobility due to severe or chronically disabling conditions (e.g., stroke, parkinson's disease, multiple sclerosis) * history of metabolic bone diseases other than osteoporosis * history of malignant disease, including solid tumors and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured) * history of paget's disease of bone * history of prior external beam or implant radiation therapy involving the skeleton * active urolithiasis or primary hyperparathyroidism
insulin glargine in type i diabetes mellitus> main study "at.lantus": a trial comparing lantus algorithms to achieve normal blood glucose targets in subjects with uncontrolled blood sugar. sub-study: "halt"(hypoglycaemia avoidance with lantus trial)

Conditions: Diabetes Mellitus, Type 1

Summary: primary objective: at.lantus main study\* * to determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(\*target number of patients for the main study:2346) halt sub-study\*\* * to test the hypothesis that titration regimens involving insulin glargine are associated with changes in the rate of symptomatic hypoglycaemic episodes together with changes in fear of hypoglycaemia as measured by the hfs-98 questionnaire in type i diabetes.(\*\*target number of patients for the sub-study: 250) secondary objectives: at.lantus main study to determine: * the incidence of symptomatic, asymptomatic and nocturnal hypoglycaemia with each treatment regimen * the difference in glycemic control as measured by hba1c and fasting blood glucose with each treatment regimen * the difference in glycemic control as measured by hba1c and fasting blood glucose between baseline and end of treatment * the safety on the use of insulin glargine in each treatment algorithm * the change in subject weight with each treatment regimen * the change in insulin doses with each treatment regimen * the change in diabetes treatment satisfaction (diabetes treatment satisfaction questionnaire, sub-study only) with each treatment regimen halt sub-study (baseline to study end) * to estimate the relationship between change in hba1c and incidence of hypoglycaemia * to examine the effect of insulin glargine on quality of life (eq-5d) in relation to incidence of hypoglycaemia * to examine the effect of insulin glargine on the hospital anxiety and depression scale (hads) in relation to the incidence of hypoglycaemia * to examine the use of the prescription plan versus standard management (no prescription plan)


Eligibility criteria:
inclusion criteria: * subjects with type 1 diabetes mellitus who require a basal (long-acting) insulin for the control of hyperglycemia, with hba1c values \> 7.0% and \< 12 %, and a body mass index (bmi) \< 40 kg/m2.
medi5752 in combination with carboplatin plus pemetrexed in unresectable pleural mesothelioma

Conditions: Unresectable Pleural Mesothelioma

Summary: this is a phase iii, randomized, open-label, multicenter, global study to determine the efficacy and safety of volrustomig (medi5752) + carboplatin + pemetrexed vs the investigator's choice of platinum + pemetrexed or nivolumab + ipilimumab in participants with unresectable pleural mesothelioma.

adult patients with histologically proven diagnosis of pleural mesothelioma with advanced unresectable disease are eligible to be enrolled. patients will be randomized 1:1 to receive volrustomig (medi5752) + carboplatin + pemetrexed or the investigator's choice of platinum+pemetrexed or nivolumab+ipilimumab, based on their histology.

Eligibility criteria:
key inclusion criteria: * participant must be ≥ 18 years at the time of screening * histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid) * advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy) * who/ecog performance status of 0 or 1 with no deterioration (that is, ecog ps\>1) over the previous 2 weeks prior to day of first dosing * has measurable disease per modified recist1.1 * has adequate bone marrow reserve and organ function at baseline key exclusion criteria: * as judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results. * active or prior documented autoimmune or inflammatory disorders * history of another primary malignancy with exceptions. * uncontrolled intercurrent illness * tuberculosis, hepatitis b (hbv) or hepatitis c (hcv), human immunodeficiency virus (hiv) infection that is not well controlled * any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment * untreated or progressive cns metastatic disease

Keywords: mesothelioma pleural mesothelioma unresectable pleural mesothelioma advanced pleural mesothelioma
do group insulin education visits reduce barriers to insulin initiation?

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this research is to determine if meeting in a group with other subjects with diabetes can reduce barriers to starting insulin.

diabetes is a common, morbid and expensive disease among veterans. achieving and maintaining adequate glycemic control can reduce the devastating complications of diabetes. unfortunately a large percentage of veterans with type 2 diabetes continue to have poorly controlled blood sugars. insulin is the most potent medication for reducing glycemia, but is not used often enough due to barriers that are both patient and provider driven. we propose to conduct a pilot study to evaluate the feasibility of establishing an insulin education group that would serve to educate patients about insulin, to initiate insulin in a group setting, and to provide appropriate follow-up of those who start insulin. if the intervention is successful, we plan to develop a multicenter study to test rigorously the effect of this approach. specific aims: to determine if psychological barriers to insulin initiation in patients with uncontrolled type 2 diabetes are favorably affected by a group insulin education and insulin initiation visit, as measured by the barriers to insulin treatment (bit) questionaire before and after the intervention. to evaluate the feasibility of the intervention as measured by the percent of patients who are referred to the class, but either cancel without rescheduling or fail to report and the percent of patients who begin insulin. to evaluate the safety of the intervention as measured by the proportion of patients experiencing hypoglycemic symptoms; proportion of patients requiring sugar intake to manage hypoglycemia; and the proportion of patients requiring assistance to manage hypoglycemia.

Eligibility criteria:
inclusion criteria: * primary care patient at mcguire veterans affairs medical center in richmond, virginia * age \> 18 years * inadequately controlled diabetes (hba1c \> 8.0%) and not on insulin (using most recent hba1c, within 1 month of the first visit) * primary care provider referral to insulin initiation/education group * patient brings home glucose readings to first visit exclusion criteria: * patient is reluctant to participate in a group visit for any reason * patient unwilling to sign consent form

Keywords: insulin teaching
tdf combined with ldt for the treatment of hbeag-positive hepatitis b patients with poor response to tdf for 12 months

Conditions: Chronic Hepatitis B

Summary: studies have shown that the hbeag seroconversion rate of hbeag positive chronic hepatitis b with tenofovir for one year's treatment was 17.8% and the negative conversion rate of their hbeag and hbv dna were 20.0% and 97.6%. the hbeag seroconversion rate of these patients was lower.clinically, most patients need to take tenofovir for a long time, which may cause serious complications such as renal function damage,with decreased therapy compliance and increased cost of treatment.in the course of tenofovir treatment, it is common that hbv-dna negative patients with hbeag being down poor or staying at a low positive level for a long time keep taking the medicine. therefore, it is significant to increase the hbeag seroconversion rate of tenofovir during the clinical treatment. telbivudine has a strong antiviral effect.studies have shown that the hbeag seroconversion rate of hbeag positive chb for one year was 25%, which was higher than other nucleosides, and it could also improve the damaged renal function to a certain extent.the hbeag seroconversion rate of patients with poor response to tenofovir for 12 months could be still poor if for 24 months . therefore, this study is to observe the efficacy of these patients combined with telbivudine.

this is an open, multicenter, exploratory and real-world clinical study. it will be carried out in patients with poor response (hbv dna \> 2x103iu / ml) to tenofovir for 12 months. after one -week screening period, patients will be randomly assigned 1:1 to control and experimental groups. the control group takes tenofovir for 12 months while the experimental group takes tenofovir combined with telbivudinefor 12months .

Eligibility criteria:
inclusion criteria: 1. male or female patients, aged 18 to 70 years, including 18 and 70 years old; 2. patients with poor response to tenofovir for 12 months did not obtained hbeag seroconversionpatients with poor response to tenofovir for 12 months who didn't obtain hbeag seroconversion choosed to continue taking tenofovir or take tenofovir combined with tbl for 12months; 3. persons were willing to sign informed consent and comply with medication regimen and follow-up. exclusion criteria: 1. co-infectious with hepatitis a, hepatitis c, hepatitis d, hepatitis e or hiv; 2. in the decompensated stage of liver cirrhosis, such as ascites, varicose bleeding or hepatic encephalopathy; 3. with malignant tumors (including hepatocellular carcinoma); 4. concomitant with other liver diseases, such as alcoholic liver disease, autoimmune disease, or other systemic diseases involving the liver, such as hemochromatosis, alpha-1 antitrypsin deficiency, or wilson disease; 5. during the study period, chronic systemic steroid drugs are required or may be used under any medical conditions; there are any other factors that the researcher thinks are not suitable for inclusion in the study, or that may affect the patient's participation or completion of the study.